Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

NCT ID: NCT00112463

Last Updated: 2017-06-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-01-07
• Study Completion Date: 2008-10-23

Brief Summary

This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma. Drugs used in chemotherapy, such as depsipeptide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Detailed Description

PRIMARY OBJECTIVES:

I. To estimate the response rates of metastatic or unresectable soft tissue sarcomas to single-agent depsipeptide.

II. To estimate the time to progression of metastatic or unresectable soft tissue sarcomas to single-agent depsipeptide.

III. To evaluate the scope and extent of acute toxicities associated with single-agent depsipeptide when given to patients with soft tissue sarcomas.

OUTLINE: This is a multicenter study.

Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.

After completion of study treatment, patients are followed up every 2 months.

Conditions

Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Hemangiopericytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Gastrointestinal Stromal Tumor; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (single-agent depsipeptide)

Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.

Group Type: EXPERIMENTAL

romidepsin

Intervention Type: DRUG

DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.

Interventions

romidepsin

DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.

Intervention Type: DRUG

Other Intervention Names

FK228; FR901228; Istodax

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed soft tissue sarcoma (STS), including, but not limited to, the following histologies:

• Gastrointestinal stromal tumors (GIST)

• Refractory to imatinib mesylate
• Desmoplastic small round cell tumors
• Clear cell sarcoma
• Extraskeletal osteosarcoma*
• Extraskeletal Ewing's sarcoma*
• Extraskeletal (myxoid) chondrosarcoma*
• Secondary STS (e.g., radiation-induced STS or neurofibrosarcoma due to neurofibromatosis) allowed
• Metastatic or unresectable disease
• No standard curative therapy exists
• Patients with GIST must have received and progressed on imatinib mesylate
• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
• No known brain metastases
• Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2
• Performance status - Karnofsky 50-100%
• More than 3 months
• White blood cells (WBC) ⥠3,000/mm^3
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ⤠2.5 times upper limit of normal (ULN)
• Bilirubin normal
• Creatinine < 1.5 times ULN
• Creatinine clearance ≥ 60 mL/min
• QTc ≤ 480 msec

Exclusion Criteria

• No cardiac abnormalities (e.g., congenital long QT syndrome)
• No myocardial infarction within the past year
• No history of coronary artery disease (e.g., angina Canadian Class II-IV or positive stress imaging study)
• No cardiac ischemia (ST depression >2 mm) by electrocardiogram (ECG)
• No New York Heart Association Class II-IV congestive heart failure
• Ejection fraction > 50% by multi gated acquisition scan (MUGA) scan or echocardiogram
• No history of sustained ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, or cardiac arrest unless controlled by an automatic implantable cardioverter defibrillator
• No hypertrophic or restrictive cardiomyopathy from prior treatment or other causes
• No significant left ventricular hypertrophy
• No uncontrolled hypertension (i.e., blood pressure ≥ 160/95 mm Hg)
• No cardiac arrhythmia requiring anti-arrhythmic medication

• Beta blocker or calcium channel blocker allowed
• Patients on digitalis that cannot be discontinued not allowed
• No Mobitz II second degree block without a pacemaker (first degree or Mobitz I second degree block, bradyarrhythmias, or sick sinus syndrome require Holter monitoring and evaluation by cardiology)
• No uncontrolled dysrhythmia
• No poorly controlled angina
• No other cardiac disease
• No history of allergic reaction attributed to compounds of similar chemical or biological composition to FR901228
• No ongoing or active infection
• No iatrogenic immune deficiency or immune deficiency secondary to an underlying disorder
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Potassium ≥ 4.0 mmol/L
• Magnesium ≥ 2.0 mg/dL
• No other uncontrolled illness
• No psychiatric illness or social situation that would preclude study compliance
• No concurrent anticancer biologic agents
• No more than 1 prior chemotherapy regimen for sarcoma

• Adjuvant chemotherapy preceding disease relapse is considered 1 prior chemotherapy regimen
• Patients with GIST may have received up to 3 prior chemotherapy regimens comprising imatinib mesylate and/or sunitinib malate provided no other chemotherapy agents were used
• No prior FR901228 (depsipeptide)
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No prior cumulative doxorubicin dose > 500 mg/m^2
• No other concurrent anticancer chemotherapy
• At least 4 weeks since prior radiotherapy
• No concurrent anticancer radiotherapy
• At least 4 weeks since prior surgery
• No prior organ transplantation
• Recovered from all prior therapy
• No concurrent medications that cause QTc prolongation
• No concurrent combination highly active anti-retroviral therapy for HIV-positive patients
• No other concurrent drugs known to have histone deacetylase inhibitor activity (e.g., sodium valproate)
• No other concurrent investigational agents
• No other concurrent anticancer agents

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul Savage

Role: PRINCIPAL_INVESTIGATOR

Wake Forest University Health Sciences

Other Identifiers

NCI-2012-01037

Identifier Type: REGISTRY

Identifier Source: secondary_id

CCCWFU 71103

Identifier Type: OTHER

Identifier Source: secondary_id

6319

Identifier Type: REGISTRY

Identifier Source: secondary_id

U10CA081851

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P30CA012197

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2012-01037

Identifier Type: -

Identifier Source: org_study_id

NCT01645683

Identifier Type: -

Identifier Source: nct_alias